AFT Completes Successful Development of Maxigesic Rapid

Market release
1 March 2019

AFT Pharmaceuticals Completes Successful Development of
Maxigesic Rapid

AFT Pharmaceuticals has successfully completed development of a faster release version of
its dual action pain-killer, Maxigesic.

Maxigesic comprises two active ingredients, paracetamol [acetaminophen] and ibuprofen in
a synergistic ratio. Following an agreement which in-licensed specialist patented technology,
a new formulation of Maxigesic has been developed which releases one of the key
components, ibuprofen, much faster in comparison with a standard Maxigesic tablet.

“We see this as an advantage as new technology allows the ibuprofen component to be
dissolved into the stomach much faster” said Dr Hartley Atkinson, CEO of AFT
Pharmaceuticals.

Additional Intellectual Property has been generated around these findings and a further
patent application has also been recently filed. “Following a recent FDA meeting, the first
registration of Maxigesic Rapid is underway and expected within the next 12 months in the
USA” noted Dr Atkinson.

The US market is of particular interest as it is the largest pharmaceutical market in the world.
The market defined by Euromonitor in 2018 for oral dose forms of analgesics for adults is
close to US$4 billion.

[End of Release]

For more information:

Dr Hartley Atkinson,
CEO, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232
Email: hartley@aftpharm.com

About MAXIGESIC®
MAXIGESIC® is a unique, patented combination of paracetamol and ibuprofen that provides
fast, effective double action pain relief from a wide range of pain.
https://www.aftpharm.com

About AFT
AFT is a growing multinational pharmaceutical business with a broad range of products, both
developed itself and in-licensed from third parties. AFT’s products cover all major
pharmaceutical distribution channels: over-the-counter, prescription and hospital.
Historically, AFT’s home markets have been Australia, New Zealand and South-East Asia.
However the company is out-licensing its own products to licensees and distributors to sell in
an increasing number of countries around the world. The company’s intensive Research and
Development programme forms the basis of its international sales strategy. For more
information about the company, visit
aftpharm.com